natgillin/translations-raw huggingface dataset:
• Kombination af omfattende svært udslæt, følelse af at være syg, feber, højt indhold af visse hvide blodlegemer eller gul hud eller øjne (tegn på gulsot) med stakåndethed, brystsmerter/ubehag, svært nedsat urinproduktion og tørst osv. (tegn på en behandlingsrelateret allergisk reaktion). 
• Combination of a widespread severe rash, feeling sick, fever, high level of certain white blood cells or yellow skin or eyes (signs of jaundice) with breathlessness, chest pain/discomfort, severely decreased urine output and feeling thirsty etc. (signs of a treatment-related allergic reaction).
Aktive stoffer, hvis plasmakoncentration kan ændres af imatinib Imatinib øger gennemsnitligt Cmax og AUC af simvastatin (et CYP3A4-substrat) henholdsvis 2 og 3,5 gange, hvilket indikerer, at imatinib hæmmer CYP3A4. 
Active substances that may have their plasma concentration altered by imatinib Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indicating an inhibition of the CYP3A4 by imatinib.
• Føle sig svimmel eller besvime (tegn på lavt blodtryk). 
• Feeling light-headed, dizzy or fainting (signs of low blood pressure).
Imatinibs farmakokinetik er evalueret i dosisintervallet: 25-1.000 mg. Plasmafarmakokinetiske profiler blev analyseret på dag 1 og på enten dag 7 eller dag 28, hvor plasmakoncentrationerne havde nået steady-state. 
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.
Selvom resultaterne fra en farmakokinetisk analyse viste, at der var en betydelig variation mellem forsøgspersoner, øgede den gennemsnitlige eksponering af imatinib sig ikke hos patienter med varierende grad af nedsat leverfunktion, sammenlignet med patienter med normal leverfunktion (se pkt. 
Although the results of pharmacokinetic analysis showed that there is considerable inter-subject variation, the mean exposure to imatinib did not increase in patients with varying degrees of liver dysfunction as compared to patients with normal liver function (see sections 4.2, 4.4 and 4.8).
Der skal udvises forsigtighed, når imatinib gives samtidig med CYP3A4-familien. 
Caution should be taken when administering imatinib with inhibitors of the CYP3A4 family.
Imatinib medac hæmmer væksten af disse celler i en vis undergruppe af disse sygdomme. 
Imatinib medac inhibits the growth of these cells in a certain subtype of these diseases.
Alle patienter opnåede komplet hæmatologisk respons, cytogenetisk repons og/eller klinisk respons. 
All patients achieved complete haematological response, cytogenetic response and/or clinical response.
Der er ingen kontrollerede forsøg med pædiatriske patienter med HES/CEL. 
There are no controlled trials in paediatric patients with HES/CEL.
Der er kun begrænset erfaring med imatinib hos patienter med MDS/MPD forbundet med PDGFR-omlejring (se pkt 5.1). 
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
Nedsat leverfunktion: Imatinib metaboliseres primært i leveren. 
Hepatic insufficiency: Imatinib is mainly metabolised through the liver.
• Symptomer på infektioner såsom feber, kraftige kulderystelser, ondt i halsen eller sår i munden. 
• Signs of infection such as fever, severe chills, sore throat or mouth ulcers.
Ved doser >6 mg/kg, sås hos rotter i 13-ugers undersøgelsen hyperplasi af det transitoriske epithel i nyrepapillerne og i urinblæren, uden ændringer i serum- eller urinparametre. 
In rats, hyperplasia of the transitional epithelium in the renal papilla and in the urinary bladder was observed at doses > 6 mg/kg in the 13-week study, without changes in serum or urinary parameters.
Analysen bekræftede, at imatinib-eksponeringen hos børn, som fik 260 mg/m² en gang dagligt (højst 400 mg en gang dagligt) eller 340 mg/m² en gang dagligt (højst 600 mg en gang dagligt), svarede til eksponeringen hos voksne, som fik imatinib 400 mg eller 600 mg en gang dagligt. 
The analysis confirmed that exposure of imatinib in paediatric patients receiving 260 mg/m once daily (not exceeding 400 mg once daily) or 340 mg/m once daily (not exceeding 600 mg once daily) were similar to those in adult patients who received imatinib 400 mg or 600 mg once daily.
Hvis en af disse undersøgelser viser abnormalitet, bør det overvejes at kombinere imatinib med profylaktisk brug af systemisk steroid (1-2 mg/kg) i en til to uger ved behandlingsstart. 
If either is abnormal, follow-up with a cardiology specialist and the prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with imatinib should be considered at the initiation of therapy.
FREMSTILLERENS BATCHNUMMER Lot 
BATCH NUMBER Lot:
Plasmafarmakokinetik 
Plasma pharmacokinetics
5 Pleural effusion blev observeret oftere hos patienter med GIST og hos patienter med transformeret CML (CML-AP og CML-BC) end hos patienter med kronisk CML. 
5) Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML.
• Philadelphia-kromosom-positiv akut lymfoblastær leukæmi (Ph-positiv ALL). 
• Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL).
I den kliniske Philadelphia-kromosom-positiv (Ph undersøgelse var 38 % af patienterne ≥60 år, og 12 % af patienterne var ≥70 år. 
In the clinical study 38 % of patients were ≥ 60 years of age and 12 % of patients were ≥ 70 years of age.
Der anbefales en dosis på 340 mg/m² dagligt til børn med Ph+ ALL (totaldosis på 600 mg må ikke overskrides). 
The dose of 340 mg/m daily is recommended for children with Ph+ ALL (not to exceed the total dose of 600 mg).
Det er en potent protein-kinasehæmmer, der hæmmer aktiviteten af BcrAbl-tyrosinkinase (TK) såvel som adskillige TK-receptorer: Kit, receptoren for stamcellefaktoren (SCF) kodet for af c-kit proto-onkogenet, discoidin-domænereceptorerne (DDR1 og DDR2), receptoren for den kolonistimulerende faktor (CSF-1R) og receptorerne for trombocytafledte vækstfaktorer alfa og beta (PDGFR-alfa og PDGFR-beta). 
Imatinib is a small molecule protein kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase (TK), as well as several receptor TKs: Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta).
Pakninger indeholdende 30 hårde kapsler. 
Packs containing 30 hard capsules.
1, sinuitis, cellulitis, infektioner i øvre luftveje, influenza, urinvejsinfektion, gastroenteritis, sepsis 
1, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis
Palmoplantar erytrodysæstesi syndrom*, lichenoid keratosis*, lichen planus*, toksisk epidermal nekrolyse*, medikamentelt udslæt med eosinofili 
Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms
• voksne og børn med nydiagnosticeret Philadelphia-kromosom-positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. 
• adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
• voksne patienter med refraktært hypereosiniphil syndrom (HES) og/eller kronisk eosinofil leukæmi (CEL) med FIP1L1-PDGFRα-omlejring. 
• adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Imatinib medac hæmmer væksten af disse celler. 
Imatinib medac inhibits the growth of these cells.
Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) eller sjældne (kan forekomme hos op til 1 ud af 1.000 personer): 
Uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people):
Der anbefales en dosering på 340 mg/m² dagligt til børn med CML i kronisk fase og i accelereret fase (må ikke overskride en total dosering på 800 mg). 
340 mg/m daily is recommended for paediatric patients with chronic phase CML and accelerated phase CML (not to exceed the total dose of 800 mg).
Derudover erfaringer der efter markedsføring er rapporteret gastric antral vascular ecstasia (GAVE), en sjælden form for gastrointestinal blødning, hos patienter med CML, ALL og andre sygdomme (se pkt. 
In addition, gastric antral vascular ectasia (GAVE), a rare cause of gastrointestinal haemorrhage, has been reported in post-marketing experience in patients with CML, ALL and other diseases (see section 4.8).
Pakninger indeholdende 60 hårde kapsler. 
Packs containing 60 hard capsules.
Vedligeholdelse (8-ugers cykler) Cyklus 1-4 
Maintenance (8-week cycles) Cycles 1-4
De hyppigst observerede alvorlige bivirkninger hos børn med CML var grad 3 eller 4 cytopenier med neutropeni, trombocytopeni og anæmi. 
In paediatric CML patients the most frequent toxicities observed were grade 3 or 4 cytopenias involving neutropenia, thrombocytopenia and anaemia.
Musklesvaghed, arthritis, rabdomyolyse/myopati 
Muscular weakness, arthritis, rhabdomyolysis/myopathy
Den almindelige startdosis i behandlingen af CML i blastkrise er 600 mg, der tages som 6 kapsler med 100 mg (eller 1 kapsel med 400 mg plus 2 kapsler med 100 mg) én gang dagligt. 
The usual starting dose in treatment in CML in blast crisis is 600 mg, to be taken as 6 capsules of 100 mg (or 1 capsule of 400 mg plus 2 capsules of 100 mg) once a day.
• Bleghed, føle sig træt og stakåndet og have mørk urin (tegn på lavt antal røde blodceller). 
• Pale skin, feeling tired and breathlessness and having dark urine (signs of low levels of red
Hvis dosis tolereres, kan den øges ved manglende effekt (se pkt. 
If tolerated, the dose can be increased for lack of efficacy (see sections 4.4 and 5.2).
De aktuelle dosisanbefalinger er baseret på et lille antal pædiatriske patienter (se pkt. 
The dose recommendation is currently based on a small number of paediatric patients (see sections 5.1 and 5.2).
• Næseblod. 
• Nose bleeds.
Denne hæmning er ikke observeret in vivo efter administrationen af 400 mg imatinib og 1 g paracetamol. 
This inhibition has not been observed in vivo after the administration of imatinib 400 mg and paracetamol 1000 mg. Higher doses of imatinib and paracetamol have not been studied.
Svimmelhed, paræstesi, smagsforstyrrelser, hypoæstesi 
Dizziness, paraesthesia, taste disturbance, hypoaesthesia
Recidiverendet/refraktær Ph+ ALL: Da imatinib blev brugt som enkeltstofbehandling ved recidiverende/refraktær Ph+ ALL var resultatet hos 53 ud af 411 evaluerbare patienter en hæmatologisk responsrate på 30 % (9 % komplet) og en væsentlig cytogenetisk responsrate på 23 %. 
Relapsed/refractory Ph+ ALL: When imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30 % (9 % complete) and a major cytogenetic response rate of 23 %.
NAVN PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN medac GmbH 
NAME OF THE MARKETING AUTHORISATION HOLDER medac GmbH
Færre end 1 % af CML-patienterne fik seponeret behandlingen permanent på grund af abnormaliteter i levertal. 
Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1 % of CML patients.
Alle behandlingsregimer inkluderer administration af steroider mod CNS profylakse Ara-C: cytosin arabinosid; CP: cyclophosphamid; DEX: dexamethason; MTX: methotrexat; 6MP: 6-mercaptopurin; VM26: teniposid; VCR: vinkristin; IDA: idarubicin; i.v. 
Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6-MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v.
Reaktivering af hepatitis B er forekommet hos kroniske bærere af hepatitis B-virus (HBV), efter at patienten har fået en BCR-ABL-tyrosinkinasehæmmer. 
Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL tyrosine kinase inhibitors.
C-mærket imatinib, genfandtes ca. 81 % af dosis inden for 7 dage i fæces (68 % af dosis) og urin (13 % af dosis). 
Based on the recovery of compound(s) after an oral 14C-labelled dose of imatinib, approximately 81 % of the dose was recovered within 7 days in faeces (68 % of dose) and urine (13 % of dose).
MTX 15 mg intrathecal, dag 1 
MTX 15 mg intrathecal, day 1;
Reaktivering af hepatitis B er beskrevet i forbindelse med behandling med BCR-ABL tyrosinkinasehæmmere. 
Hepatitis B reactivation has been reported in association with BCR-ABL TKIs.
Hypokaliæmi, øget appetit, hypofosfatæmi, nedsat appetit, dehydrering, gigt, hyperurikæmi, hyperkalcæmi, hyperglykæmi, hyponatriæmi 
Hypokalaemia, increased appetite, hypophosphataemia, decreased appetite, dehydration, gout, hyperuricaemia, hypercalcaemia, hyperglycaemia, hyponatraemia
4 Flushing var almindeligst host patienter med GIST, og blødning (hæmatom og blødning) var almindeligst hos patienter med GIST og med transformeret CML (CML-AP og CML-BC). 
4) Flushing was most common in GIST patients and bleeding (haematoma, haemorrhage) was most common in patients with GIST and with transformed CML (CML-AP and CML-BC).
Akut lymfoblastær leukæmi er en form af leukæmi, hvor visse abnorme hvide blodlegemer (kaldet lymfoblaster) vokser ukontrolleret. 
Acute lymphoblastic leukaemia is a form of leukaemia in which certain abnormal white cells (named lymphoblasts) start growing out of control.
Vedligeholdelse (8-ugers cykler) Cyklus 5 
Maintenance (8-week cycles) Cycle 5
I nogle tilfælde har dette medført akut leversvigt eller fulminant hepatitis, førende til levertransplantation eller død. 
Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome.
Hos patienter med nedsat leverfunktion (let, moderat eller svær) bør perifere blodtal og leverenzymer monitoreres omhyggeligt (se pkt. 
In patients with hepatic dysfunction (mild, moderate or severe), peripheral blood counts and liver enzymes should be carefully monitored (see sections 4.2, 4.8 and 5.2).
CML i kronisk fase, MDS/MPD (startdosis 400 mg) HES/CEL (ved 400 mg dosis) 
Chronic phase CML, MDS/MPD (starting dose 400 mg)
Imatinib kan øge plasmakoncentrationen af andre CYP3A4-metaboliserede lægemidler (for eksempel triazol-benzodiazepiner, dihydropyridin-calciumantagonister, visse HMGCoA reduktasehæmmere, såsom statiner osv.). 
Imatinib may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.).
DEX 10 mg/m² oral, dag 1-5; 
DEX 10 mg/m oral, days 1-5;
Der sås nyretoksicitet hos aber behandlet i 2 uger, inkluderende fokal mineralisering og dilatering af nyretubuli samt tubulær nefrose. 
Renal toxicity was observed in monkeys treated for 2 weeks, with focal mineralisation and dilation of the renal tubules and tubular nephrosis.
Hvis cytopeni vedvarer i 2 uger, reducér dosis yderligere til 300 mg. 
If cytopenia persists for 2 weeks, reduce further to 300 mg.
FARMAKOLOGISKE EGENSKABER 5.1 Farmakodynamiske egenskaber Farmakoterapeutisk klassifikation: Protein-kinasehæmmer, ATC-kode: L01XE01 
Pharmacotherapeutic group: protein kinase inhibitor, ATC code: L01XE01
Kontakt lægen, før du tager Imatinib medac: 
Talk to your doctor before taking Imatinib medac:
I en fertilitetsundersøgelse med hanrotter doseret i 70 dage før parring sås nedsat testikel- og epididymisvægt samt reduceret antal bevægelige sædceller ved 60 mg/kg, ca. svarende til den maksimale kliniske dosis på 800 mg/dag, baseret på legemsoverfladeareal. 
In a study of fertility, in male rats dosed for 70 days prior to mating, testicular and epididymal weights and percent motile sperm were decreased at 60 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.
Dosering ved MDS/MPD hos voksne patienter Den anbefalede dosis af imatinib er 400 mg/dag til voksne patienter med MDS/MPD. 
Posology for MDS/MPD in adult patients The recommended dose of imatinib is 400 mg/day for adult patients with MDS/MPD.
Patienter, der ikke er i stand til at synke kapslerne, (f.eks. børn), kan dispergere kapslerne i et glas med almindeligt vand eller æblejuice. 
For patients unable to swallow the capsules (e.g. paediatric patients), their content may be dispersed in a glass of still mineral water or apple juice.
• Bækkensmerter, nogle gange med kvalme og opkastninger med uventet vaginalblødning, føle sig svimmel eller besvime pga. nedsat blodtryk (tegn på problemer med dine æggestokke eller 
• Pelvic pain sometimes with nausea and vomiting, with unexpected vaginal bleeding, feeling dizzy or fainting due to low blood pressure (signs of problems with your ovaries or womb).
Imatinib ansås ikke som værende genotoksisk i in vitro bakteriecelleundersøgelse (Ames-test), i in vitro pattedyrscelleundersøgelse (muselymfom) samt i in vivo rottemikronukleusundersøgelse. 
Imatinib was not considered genotoxic when tested in an in vitro bacterial cell assay (Ames test), an in vitro mammalian cell assay (mouse lymphoma) and an in vivo rat micronucleus test.
Der bør anvendes mindste startdosis til patienter med nedsat nyrefunktion. 
Patients with renal impairment should be given the minimum starting dose.
Arytmi, atrieflimren, hjertestop, myokardieinfarkt, angina pectoris, perikardiel effusion 
Arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris, pericardial effusion
Pruritus, ansigtsødem, tør hud, erythem, alopeci, natlig svedtendens, 
Pruritus, face oedema, dry skin, erythema, alopecia, night sweats, photosensitivity
Pleuralgi, lungefibrose, pulmonal hypertension, pulmonal blødning 
Pleuritic pain, pulmonary fibrosis, pulmonary hypertension, pulmonary haemorrhage
Nøje monitorering af leverfunktionen skal udføres i tilfælde, hvor imatinib kombineres med kemoterapiregimer, som også vides at være forbundet med leverdysfunktion (se pkt. 
Hepatic function should be carefully monitored in circumstances where imatinib is combined with chemotherapy regimens also known to be associated with hepatic dysfunction (see section 4.5 and 4.8).
Nydiagnostiseret Ph+ ALL: I et kontrolleret studie (ADE10) hvor imatinib blev sammenlignet med kemoterapi-induktion hos 55 nydiagnostiserede patienter i alderen 55 år og derover, gav imatinib brugt som monoterapi anledning til en signifikant højere ratio af hæmatologisk respons end kemoterapi (96,3 % vs. 50 %, p = 0,0001). 
Newly diagnosed Ph+ ALL: In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55 newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3 % vs. 50 %; p = 0.0001).
Dosisøgning fra 340 mg/m² dagligt til 570 mg/m² dagligt (uden at overstige total dosis på 800 mg) kan overvejes ved fravær af alvorlige bivirkninger og svær ikke-leukæmirelateret neutropeni eller trombocytopeni ved følgende omstændigheder: sygdomsprogression (på ethvert tidspunkt); hvis der ikke er opnået tilfredsstillende hæmatologisk respons efter mindst 3 måneders behandling; hvis der ikke er opnået cytogenetisk respons efter 12 måneders behandling; eller ved tab af tidligere opnået hæmatologisk og/eller cytogenetisk respons. 
Dose increases from 340 mg/m daily to 570 mg/m daily (not to exceed the total dose of 800 mg) may be considered in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
9l og genoptag behandling med 200 mg/m². 
9/l, then resume treatment at 200 mg/m
• Kraftig hovedpine, svækkelse eller lammelser af lemmer eller ansigt, talebesvær, pludseligt bevidsthedstab (tegn på problemer med nervesystemet såsom blødning eller hævelse i 
• Severe headache, weakness or paralysis of limbs or face, difficulty speaking, sudden loss of consciousness (signs of nervous system problems such as bleeding or swelling in skull/brain).
Migræne, døsighed, synkope, perifer neuropati, hukommelsessvigt, iskias, restless leg syndrome, tremor, hjerneblødning 
Migraine, somnolence, syncope, peripheral neuropathy, memory impairment, sciatica, restless leg syndrome, tremor, cerebral haemorrhage
18 Gy i 10 fraktioner for patienter, som er CNS3 ved diagnosticering VCR (1,5 mg/m²/dag, i.v. 
12 Gy in 8 fractions for all patients that are CNS1 and CNS2 at diagnosis 18 Gy in 10 fractions for patients that are CNS3 at diagnosis VCR (1.5 mg/m2/day, IV): days 1, 29
Doser på 260 og 340 mg/m²/dag til børn gav samme optagelse som doser på henholdsvis 400 mg og 600 mg til voksne. 
Dosing in paediatric patients at 260 and 340 mg/m2/day achieved the same exposure, respectively, as doses of 400 mg and 600 mg in adult patients.
Øget interkranielt tryk, kramper, synsnervebetændelse 
Increased intracranial pressure, convulsions, optic neuritis
Ara-C 1.000 mg/m²/12 timer i.v. 
Ara-C 1,000 mg/m2/12 h i.v.
(1 time), dag 26, 46; Ara-C 75 mg/m² i.v. 
(1 h), days 26, 46; Ara-C 75 mg/m i.v.
• voksne patienter med Ph+ ALL med tilbagefald eller refraktær sygdom som monoterapi. 
• adult patients with relapsed or refractory Ph+ ALL as monotherapy.
Af en række potentielle samtidigt administrerede lægemidler (acetaminophen, acicolvir, allopurinol, amphotericin, cytarabin, erythromycin, fluconazol, hydroxyurea, norfloxacin, penicillin V) viste kun erythromycin (IC50 50 µm) og fluconazol (IC50 118 µm) hæmning af imatinib-metabolismen i et omfang der kunne have klinisk betydning. 
Of a panel of potential comedications (acetaminophen, aciclovir, allopurinol, amphotericin, cytarabine, erythromycin, fluconazole, hydroxyurea, norfloxacin, penicillin V) only erythromycin (IC50 50 μM) and fluconazole (IC50 118 μM) showed inhibition of imatinib metabolism which could have clinical relevance (see section 4.5).
Stoffet hæmmer selektivt proliferationen og inducerer apoptosis i Bcr-Ablpositive cellelinier såvel som i friske leukæmiceller fra patienter, der er Philadelphia-kromosom 
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and ALL patients.
• Føle sig svimmel eller svag. 
• Feeling dizzy or weak.
Total bilirubin > 3-10 ULN 
Total bilirubin: >3-10 ULN AST: any
Imatinib medac 400 mg kapsler leveres i pakninger med 30 kapsler i blister. 
Imatinib medac 400 mg capsules are supplied in packs containing 30 capsules in blisters.
Aktive stoffer, der kan øge plasmakoncentrationen af imatinib Stoffer, der hæmmer cytochrom P450 isoenzym CYP3A4-aktiviteten (f.eks. proteasehæmmere som f.eks. indinavir, lopinavir/ritonavir, ritonavir, saquinavir, teleprevir, nelfinavir, boceprevir; azolantimykotika inklusive ketoconazol, itraconazol, posaconazol, voriconazol; visse makrolider som f.eks. erythromycin, clarithromycin og telithromycin), kan nedsætte metaboliseringen og øge koncentrationen af imatinib. 
Active substances that may increase imatinib plasma concentrations Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib concentrations.
Methotrexat (20 mg/m²/uge, p.o.): dag 8, 15, 22, 29, 36, 43, 50 
Methotrexate (20 mg/m2/week, PO): days 8, 15, 22, 29, 36, 43, 50